Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
shape increases » showed increases (Expand Search), sharp increase (Expand Search), disease increases (Expand Search)
-
2461
-
2462
-
2463
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2464
-
2465
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2466
-
2467
-
2468
-
2469
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2470
-
2471
-
2472
-
2473
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2474
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2475
-
2476
-
2477
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2478
-
2479
-
2480